Lev’s Cinryze Wins Unanimous Advisory Committee Support
This article was originally published in The Pink Sheet Daily
Executive Summary
Postmarketing studies likely will be required for what could be the first U.S. treatment for hereditary angioedema.
You may also be interested in...
ViroPharma Looks To Enter HAE Market With Lev Acquisition
Pennsylvania biotech assumes FDA will split HAE orphan designation, with Cinryze winning prophylaxis indication first.
ViroPharma Looks To Enter HAE Market With Lev Acquisition
Pennsylvania biotech assumes FDA will split HAE orphan designation, with Cinryze winning prophylaxis indication first.
Jerini To Submit Complete Response Letter
With five companies in a race to control the HAE therapeutic space, three announce progress.